New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 14, 2013
10:55 EDTNBS, NBS, ONVO, ONVO, LIFE, LIFE, GSK, GSK, CELG, CELG, BAX, BAX, STEM, STEM, OSIR, OSIR, BLUE, BLUE, SGMO, SGMO, FCSC, FCSC, PSTI, PSTI, MBLTY, MBLTY, ATHX, ATHX, BTX, BTXAlliance for Regenerative Medicine to hold a meeting
2013 Stem Cell Meeting on the Mesa is being held in La Jolla, California on October 14-16 with webcasted presentations to begin on October 14 at 11 am; not all presentations may be webcasted. Webcast Link
News For NBS;ATHX;MBLTY;PSTI;FCSC;SGMO;BLUE;OSIR;STEM;BAX;CELG;GSK;LIFE;ONVO;BTX From The Last 14 Days
Check below for free stories on NBS;ATHX;MBLTY;PSTI;FCSC;SGMO;BLUE;OSIR;STEM;BAX;CELG;GSK;LIFE;ONVO;BTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 24, 2014
07:43 EDTCELGCelgene reports Q2 ABRAXANE sales increased 39%
Subscribe for More Information
07:42 EDTCELGCelgene reports Q2 REVLIMID sales increased 15%
Subscribe for More Information
07:34 EDTCELGCelgene raises FY14 adjusted EPS view to $3.60-$3.65 from $3.50-$3.60
Consensus is $3.67. Raises FY14 revenue view to $7.6B from $7.5B, consensus $7.54B. Sees Revlimid net product sales $4.95B from preview $4.9B-$5B range. Sees Abraxane net product sales $850M-$900M.
07:32 EDTCELGCelgene reports Q2 adjusted EPS 90c, consensus 89c
Reports Q2 revenue $1.87B, consensus $1.85B.
06:13 EDTGSKGlaxoSmithKline's malaria vaccine candidate accepted for EU regulatory review
Subscribe for More Information
05:32 EDTMBLTYMesoblast downgraded to Sell from Neutral at Goldman
Subscribe for More Information
July 23, 2014
16:16 EDTSGMOSangamo reiterates 2014 revenue outlook $45M-$50M, consensus $48M
Subscribe for More Information
16:15 EDTSGMOSangamo reports Q2 EPS (10c), consensus (14c)
Subscribe for More Information
15:30 EDTCELGNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
09:41 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL NFLX FB MSFT CELG TWTR TSLA VALE CNW
09:33 EDTGSKGlaxoSmithKline reports record Promacta/Revolade Q2 revenue of $92M
Subscribe for More Information
09:17 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
09:06 EDTSTEMCapital Ventures International reports 6.5% passive stake in StemCells
07:19 EDTGSKGenmab reports Q2 Arzerra net sales GBP 12.8M
Subscribe for More Information
07:12 EDTGSKGlaxoSmithKline lowers 2014 core EPS outlook to 'similar' to 2013
GSK now expects 2014 core EPS to be "broadly similar" to 2013 versus previous expectations of 4%-8% growth. It added, "Given impact of recent sustained strength of Sterling on free cash flow, share repurchases over balance of 2014 likely to be immaterial."
07:09 EDTGSKGlaxoSmithKline reports Q2 core EPS down 12% to 19.1p
Subscribe for More Information
07:09 EDTGSKMylan wins restraining order against Apotex for generic version of GSK's Paxil
Subscribe for More Information
July 22, 2014
09:55 EDTGSKLupin, private equity funds weigh bids for GSK's older drugs, Reuters reports
Subscribe for More Information
07:12 EDTCELGCelgene has upper hand in Revlimid case, says Bernstein
Subscribe for More Information
July 21, 2014
07:11 EDTGSKInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use